Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Recent Advances in Radiopharmacy"
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 9969
Special Issue Editor
Interests: radiopharmaceuticals; innovative radionuclides; theranostic; copper radiopharmaceuticals
Special Issue Information
Innovative radionuclides, such as astatine-211 and actinium-225 in therapy, or copper-64 and zirconium-89 in imaging, are becoming increasingly important in radiopharmacy. However, it is difficult to develop them for clinical application. The aim of this Special Issue is to establish the potential uses of these innovative radionuclides, to discuss new trends in radiopharmaceuticals developed with them, and to provide a basis to facilitate their use in clinical trials.
This Special Issue aims to present new trends in the use of innovative radionuclides and their applications in radiopharmacy. The physical or chemical properties of new radionuclides are sometimes unfavorable for the stability of the radiopharmaceuticals obtained with them, which limits their applications. Even if these radionuclides are recognized as being of interest by the scientific community, many questions remain to be answered. Is the growing application of actinium [225Ac] radiolabeled peptides, which are characterized by rapid pharmacokinetic distribution and elimination phases, extensible to other vectors currently used in internal radiotherapy? Is radioactive filiation compatible with non-internalized radiopharmaceuticals? What will be the place of [211At]-Astatine, currently studied at the preclinical level? Are the physical properties of [64Cu]-Copper and its particular metabolism interesting compared with [89Zr]-Zirconium? This Special Issue aims to address these questions, in order to elucidate the future applications of these radionuclides in radiopharmacy.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: innovative radionuclides and their associated radiopharmaceuticals, pharmacokinetics models for innovative radionuclides, in vivo and in vitro stability studies of innovative radionuclides, and new vectors for innovative radionuclides. We look forward to receiving your contributions.
Prof. Dr. Alain Faivre-Chauvet
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- radiopharmaceuticals with innovative radionuclides
- stability of radiopharmaceuticals
- metabolism of radiopharmaceuticals
- tumor targeting
- alpha vectorized radiotherapy
- long period PET radiopharmaceuticals